PAIN SYNDROME IN OSTEOPOROSIS TREATMENT

Abstract

Objective: to evaluate the clinical efficacy and safety of Amelotex (the international non-proprietary name of meloxicam) in patients with osteoarthrosis (OA) and recurrent synovitis.
Subjects and methods. The open randomized study included 40 patients with knee-joint OA of predominantly X-ray stages II and III, who were found to have synovitis. A study group comprised 20 patients receiving Amelotex and a control group consisted of 20 patients taking diclofenac. Amelotex was intramuscularly injected in a dose of 1,5 ml once daily for 5 days; diclofelac was intramuscularly used in a dose of 3 ml in the same regimen. No other treatment was performed during therapy with both Amelotex and diclofenac.
Results. The use of 5-day therapy with intramuscular Amelotex in gonarthrosis patients has demonstrated its symptom-modifying action that is reflected by reductions in the pain syndrome and swelling of the joint, an increase in the volume of its movements, and a lower WOMAC index, which is comparable with that in the treatment with diclofenac.
Conclusion. The results of the study suggest the good tolerability of Amelotex and its clinical efficacy in patients with OA.